The global tumor necrosis factor inhibitor drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Tumor necrosis factor is a protein found in the human body that is responsible for inflammation. Tumor necrosis factor inhibitor drugs are the pharmaceutical drugs that inhibit the physiologic response to tumor necrosis factor (it is a part of the inflammatory response). The market growth is majorly attributable to the rising prevalence of autoimmune diseases, primarily rheumatoid arthritis, psoriasis, Crohn’s disease, and cancer among others, followed by a subsequent growth in consumer awareness regarding tumor necrosis factors. Tumor necrosis factor is a key protein that significantly participates in the stimulation of the human immunity system. As proven by several clinical results, the patients suffering from autoimmune diseases such as ankylosing spondylitis and rheumatoid arthritis, have elevated levels of this factor, specifically the tumor necrosis factor.

These inhibitors are used to suppress the inflammatory response caused by tumor necrosis factor cytokines and hence are used for the treatment of inflammatory and autoimmune diseases. The role of tumor necrosis factor inhibitors in the treatment of metastatic melanomas and locally advanced soft tissue sarcomas is under investigation. The market growth is also attributed to the novel product launches, as well as the upcoming drugs pipeline. Presently, the rising usage of therapeutics such as Infliximab, Certolizumab, Etanercept, and Golimumab is the primary factor that is augmenting the growth of the global tumor necrosis factor inhibitor drugs market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Product
• By Application

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  AbbVie Inc., Amgen Inc., and Johnson & Johnson Services, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tumor Necrosis Inhibitor Drugs Market Report by Segment

By Product

• Humira
• Enbrel
• Remicade
• Simponi
• Cimzia

By Application

• Ankylosing Spondylitis 
• Crohn's Disease 
• Rheumatoid Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Juvenile Arthritis
• Ulcerative Colitis

Global Tumor Necrosis Inhibitor Drugs Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa